Whitley R J
School of Medicine, Department of Pediatrics, University of Alabama, Birmingham 35294-0011.
Pathol Biol (Paris). 1992 Sep;40(7):729-34.
Neonatal herpes simplex virus (HSV) infections are of increasing incidence in North America, now occurring at a rate of approximately one in 3,500 to one in 5,000 deliveries per year. Disease manifests as one of three forms; namely, infection: localized to the skin, eye and mouth (SEM), encephalitis (CNS), or disseminated disease. With the advent of antiviral therapy, it has become possible to decrease mortality and improve morbidity for babies suffering from infection. Advances in antiviral therapy have allowed for prevention of disease progression beyond states of SEM involvement. Furthermore, life threatening infections of the CNS or of multiple organs, have mortality with either acyclovir or vidarabine therapy. Now approximately 15% (CNS) and 50% (disseminated disease) of babies die from neonatal HSV disease. The results of ongoing studies in the United States will summarize the pathogenesis and treatment of neonatal HSV infection.
北美新生儿单纯疱疹病毒（HSV）感染的发病率正在上升，目前每年的发生率约为每3500至5000例分娩中有1例。疾病表现为三种形式之一；即感染：局限于皮肤、眼睛和口腔（SEM）、脑炎（CNS）或播散性疾病。随着抗病毒治疗的出现，降低患有感染的婴儿的死亡率并改善其发病率已成为可能。抗病毒治疗的进展使得能够预防疾病进展到超出SEM受累状态。此外，中枢神经系统或多个器官的危及生命的感染，使用阿昔洛韦或阿糖腺苷治疗均有死亡率。现在，约15%（中枢神经系统感染）和50%（播散性疾病）的婴儿死于新生儿HSV疾病。美国正在进行的研究结果将总结新生儿HSV感染的发病机制和治疗方法。
